Syndax Pharmaceuticals (SNDX) announced that it has secured an exclusive global license to Brussels, Belgium-based UCB's UCB6352, a high affinity antibody that binds to the colony stimulating factor 1 receptor (CSF-1R). In preclinical studies, inhibiting CSF-1R signaling showed an anti-tumor immune response. According to the terms of the agreement, UCB will receive an upfront payment, milestones and tiered royalties on net sales. Syndax will be responsible for development, manufacturing and worldwide commercialization. Financial terms of the deal were not disclosed.